Nanochon secured commitments to close an oversubscribed funding round, bringing its total capital raised to date to $11.3 million.
The company has developed the Chondrograft implant that allows for immediate weight-bearing and motion in the treatment of lost or damaged cartilage.
Nanochon intends to use the funds to sustain its first in-human clinical study in Canada, deepen research and development efforts, and begin planning for its future pivotal trial.
The company will commence a phase I trial in Canada in coming weeks for Chondrograft which will evaluate safety and efficacy in a prospective, 10-patient, early feasibility study for use in knee cartilage restoration in eligible patients between 22 and 60 years of age having femoral condyle and/or trochlea articular cartilage lesions who have failed conservative therapy, in addition to meeting other criteria.
“We’re both honored and humbled to oversubscribe another funding round,” says Ben Holmes, CEO and co-founder. “The capital commitments from our investors speak volumes about their confidence in the work we’re doing to shift the paradigm of cartilage restoration. Not only do we have strong financial backing, but these partners also offer us support in commercial and regulatory strategies as well.”
This latest round was led by cultivate(MD), with significant contributions from The University of Virginia UVA Seed Fund, WSGR, Wealthing VC Fund, and others.
Nanochon secured commitments to close an oversubscribed funding round, bringing its total capital raised to date to $11.3 million.
The company has developed the Chondrograft implant that allows for immediate weight-bearing and motion in the treatment of lost or damaged cartilage.
Nanochon intends to use the funds to sustain its first...
Nanochon secured commitments to close an oversubscribed funding round, bringing its total capital raised to date to $11.3 million.
The company has developed the Chondrograft implant that allows for immediate weight-bearing and motion in the treatment of lost or damaged cartilage.
Nanochon intends to use the funds to sustain its first in-human clinical study in Canada, deepen research and development efforts, and begin planning for its future pivotal trial.
The company will commence a phase I trial in Canada in coming weeks for Chondrograft which will evaluate safety and efficacy in a prospective, 10-patient, early feasibility study for use in knee cartilage restoration in eligible patients between 22 and 60 years of age having femoral condyle and/or trochlea articular cartilage lesions who have failed conservative therapy, in addition to meeting other criteria.
“We’re both honored and humbled to oversubscribe another funding round,” says Ben Holmes, CEO and co-founder. “The capital commitments from our investors speak volumes about their confidence in the work we’re doing to shift the paradigm of cartilage restoration. Not only do we have strong financial backing, but these partners also offer us support in commercial and regulatory strategies as well.”
This latest round was led by cultivate(MD), with significant contributions from The University of Virginia UVA Seed Fund, WSGR, Wealthing VC Fund, and others.
Copy to clipboard 
